June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Pain as presenting feature of uveal melanoma
Author Affiliations & Notes
  • Pukhraj Rishi
    Ocular Oncology Service, Wills Eye Institute, Philadelphia, PA
    Sankara Nethralya, Chennai, India
  • Carol Shields
    Ocular Oncology Service, Wills Eye Institute, Philadelphia, PA
  • Kaitlin Patrick
    Ocular Oncology Service, Wills Eye Institute, Philadelphia, PA
  • Mohammed Khan
    Ocular Oncology Service, Wills Eye Institute, Philadelphia, PA
  • Jerry Shields
    Ocular Oncology Service, Wills Eye Institute, Philadelphia, PA
  • Footnotes
    Commercial Relationships Pukhraj Rishi, None; Carol Shields, None; Kaitlin Patrick, None; Mohammed Khan, None; Jerry Shields, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pukhraj Rishi, Carol Shields, Kaitlin Patrick, Mohammed Khan, Jerry Shields; Pain as presenting feature of uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe the clinical features and outcomes of patients with pain from underlying uveal melanoma.

Methods: Retrospective case series of 9 patients.

Results: The mean patient age at presentation was 62 years (median 62 years, range 41-83 years). The pain manifested in the periocular region (n=9) and additionally as diffuse ipsilateral headache (n=5). On a scale of 0-10, the average pain score was 7.5 (median 9, range 2-10) and four patients reported pain severity at maximum (10/10). The average duration of pain was 27 days (median 7, range 2-180 days). Visual acuity was reduced in 8 of 9 eyes. The melanoma was located in the ciliary body (n=3) or choroid (n=6). The mean tumor basal diameter was 18 mm (median 18 mm, range 14-24 mm) and mean tumor thickness was 7 mm (median 6 mm, range 5-11 mm). Clinical features of spontaneous melanoma regression was evident in all cases (n=9). Treatment included plaque radiotherapy (n=5), enucleation (n=3) and one patient refused therapy (n=1). Following therapy, all patients were relieved of pain.

Conclusions: Ocular pain or headache can be the initial manifestation of uveal melanoma. Following ocular therapy, pain symptoms are relieved.

Keywords: 744 tumors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×